Bayer and Thermo Fisher Scientific Partner to Develop NGS-Based Companion Diagnostic Assays (CDx)
Shots:
- Bayer and Thermo Fisher Scientific have joined forces for developing next-generation sequencing (NGS)-based companion diagnostic assays (CDx) for which the companies did not disclose the financial terms
- The partnership will develop CDx by leveraging Thermo Fisher’s Oncomine Dx Express Test on the Ion Torrent Genexus Dx System having the ability to deliver patient’s tumor or liquid biopsy outcomes in <24hrs.
- The collaboration further aims at increasing patient access to Bayer’s personalized cancer treatment by providing decentralized genomic testing and rapid turnaround time
Ref: Bayer | Image: Bayer
Related News:- Thermo Fisher Scientific Collaborates with Janssen to Co-Develop CDx for Multiple Cancer Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
